
According to data from Benzinga Pro, during Q4, CASI Pharmaceuticals's (NASDAQ:CASI) reported sales totaled $9.16 million. Despite a 46.15% increase in earnings, the company posted a loss of $5.39 million. CASI Pharmaceuticals collected $8.11 million in revenue during Q3, but reported earnings showed a $10.02 million loss.